NCT03136770已完成不适用
A Randomized, Open-label, Two-way Crossover Study to Assess the Pharmacokinetics and Safety of CK-30 600 mg (Compound K) and Red Ginseng Extracts 2.94 g After a Single Oral Dose in Healthy Male Volunteers
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 25
- 试验地点
- 2
- 主要终点
- Pharmacokinetics (Cmax)
研究概览
简要总结
A study to assess the pharmacokinetics and safety of CK-30 600 mg (Compound K) and red ginseng extracts 2.94 g after a single oral dose in healthy male volunteers
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 19 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male Koreans between 19 and 45 years of age at the screening
- •A body weight of greater than 55 kg, and a body mass index (BMI) of between 18.0 and 27.0, wherein BMI (kg/m2) = Weight (kg) / [Height (m)]2
- •Full understanding of all the information regarding this clinical trial after listening to a detailed explanation, deciding to participate in the clinical trial by one's own will, and signing a written consent to comply with the precautions
排除标准
- •History of herbal medicine including ginseng and red ginseng extracts within 2 weeks before the first administration of the IP
- •Present condition or history of any clinically significant disease in the liver, nervous system, immune system, respiratory system, or endocrine system; hematologic or oncologic disease; cardiovascular disease; or psychiatric disorder (mood disorder, obsessive-compulsive disorder, etc.)
- •Clinical evidence or history of gastrointestinal disease (including Crohn's disease, gastric ulcer, and acute or chronic pancreatitis) or history of gastrointestinal surgery (except for appendectomy or hernia surgery) that could affect the pharmacokinetic and safety assessment of the IP
- •Clinical evidence of genetic disorders such as galactose intolerance, Lapp lactose deficiency, and/or glucose-galactose malabsorption
- •History of hypersensitivity, including drug allergy (red ginseng extracts, aspirin, antibiotics, etc.), or history of clinically significant hypersensitivity
- •Meeting the following criteria at the screening: Serum AST (SGOT) or ALT (SGPT) > 1.5 times the upper normal limit
- •History of drug abuse, or a positive reaction to an abusive drug in a urine drug screening
- •Having taken any prescribed medicine or herbal supplement within two weeks before the first administration of the IP, or any non-prescribed medicine or vitamin supplement within one week before the first administration of the IP (If the other conditions were satisfied, the subject could be deemed eligible for the trial at the discretion of the investigator.)
- •Participation in and administration of the IP of another clinical trial within three months before the first administration of the IP
- •Donation of a unit of blood within two months, or of blood components within one month, or receipt of a blood transfusion within one month before the first administration of the IP
- •Consumption of more than 21 units of alcohol per week (one unit being 10 g of pure alcohol) or inability to abstain from drinking alcohol during the study period
- •History of smoking 10 cigarettes per day within three months before the first administration of the IP (Subjects who quit smoking for at least three months before the first administration of the IP can still be enrolled in the trial.) or subjects who are not able to quit smoking from 24 hours before hospitalization to discharge.
- •Consumption of grapefruit-containing products within 24 hours before the hospitalization or inability to abstain from consuming grapefruit-containing products during the study period
- •Subjects who are not able to abstain from drinking caffeine-containing products (coffee, tea), carbonated drinks, nutrient tonics during the study period
- •For females, plan to conceive or become pregnant, or inability to use an appropriate method of contraception (e.g., sterilization operation of the subject or his partner, intrauterine device of the partner, a barrier contraceptive method, or a combination of the diaphragm and condom methods) during the study period
- •Assessment as ineligible by the investigator based on the results of the clinical laboratory tests or other assessments
结局指标
主要结局
Pharmacokinetics (Cmax)
时间窗: Total 16 days
Pharmacokinetics of CK-30 and Red ginseng extracts
Pharmacokinetics (AUClast)
时间窗: Total 16 days
Pharmacokinetics of CK-30 and Red ginseng extracts
次要结局
- Safety and tolerability (Number of participants with treatment-related adverse events)(Total 16 days)
研究者
In-Jin Jang, MD, PhD
Professor
Seoul National University Hospital
研究点 (2)
Loading locations...
相似试验
已完成
不适用
A prospective double-blind randomized controlled study to examine the effects of Korean red ginseng on biological aging indicators and antioxidants in Korean postmenopausal women.KCT0006506Yonsei University Health System, Gangnam Severance Hospital63
已完成
4 期
The Effect of Korean Red Ginseng Supplementation on Glucose ControlDiabetesNCT01911663Yonsei University60
已完成
1 期
Effect of Red Ginseng Extract on Changes in Indicators of Immune Function in Vietnamese Healthy VolunteersHealthyNCT05480774Centre of Clinical Pharmacology, Hanoi Medical University101
已完成
1 期
Bioequivalence Study (Candesartan 16 mg and Amlodipine 5 mg) - BHypertensionNCT02811731Chong Kun Dang Pharmaceutical32
已完成
1 期
Bioequivalence Study (Candesartan 8 mg and Amlodipine 5 mg)HypertensionNCT02186496Chong Kun Dang Pharmaceutical32